Slide 1: JADE101 Phase 1 Interim Data Conference Call
JADE101 Phase 1 Interim Data Conference Call June 1, 2026 Nasdaq: jbio Exhibit 99.1
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements Certain statements contained in or made orally during this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisi
Slide 3: JADE101 Phase 1 study met or exceeded objectives
JADE101 Phase 1 study met or exceeded objectives JADE101 Clinical data support potential for every-12-week subcutaneous dosing with best-in-class, disease-modifying potential Data cut off: April 14, 2026 SC – Subcutaneous; HV – Healthy Volunteer; TMDD – Target-Mediated Drug Disposition; ADA – Anti-D
Slide 4: Half-life extension through validated YTE Fc modification
Half-life extension through validated YTE Fc modification Longer exposure intended to maximize clinical activity and reduce dosing interval to no more frequently than every 8 weeks Potentially best-in-class properties of JADE101 Fully-human, ultra-high binding affinity, and extended half-life Notes:
Slide 5: IgAN is a $20B+ potential market in the U.S. alone
IgAN is a $20B+ potential market in the U.S. alone ~169K+ IgAN patients in the U.S., with 60-75% requiring treatment per international guidelines ~1M+ global patients, significant ex-U.S. market potential Notes: Per KDIGO guidelines, treatment should be initiated in all cases where patients have pro
Slide 6: High lifetime risk of end-stage kidney disease
High lifetime risk of end-stage kidney disease A need for effective and convenient therapies for lifelong treatment IgAN is typically diagnosed in young adults between the ages of 16 and 35; higher proteinuria is associated with greater risk of kidney failure Lifetime risk of progression to end-stag
Slide 7: Updated KDIGO guidelines position the anti-APRIL class as foundational therapy in IgAN
Updated KDIGO guidelines position the anti-APRIL class as the foundational therapy in IgAN KDIGO updates: Expected to increase IgAN diagnosis Expand at-risk patient population requiring treatment Lower proteinuria treatment target to <0.5 g/day, preferably <0.3 g/day Require targeted therapies that
Slide 8: IgA responses are consistent between HVs and IgAN patients and predictive of clinical activity
IgA responses are consistent between HVs and IgAN patients and predictive of clinical activity IgA reduction in HVs is highly correlated with IgA reduction in IgAN patients at multiple time points… …and early IgA reduction further correlates with W36 UPCR reduction, in IgAN patients Jade101 Notes: S
Slide 9: Interim Phase 1 Data
JADE101 Interim Phase 1 Data
Slide 10: Phase 1 study ongoing
JADE101 Phase 1 study ongoing Design Randomized, double-blind, placebo-controlled Single ascending dose Subcutaneous administration (175 mg/mL) Population 32 healthy adult volunteers N=8 per cohort (6:2 active:placebo) Objectives Primary: Safety and tolerability Secondary: Pharmacokinetics Explorato
Slide 11: Baseline characteristics were typical of healthy volunteers
Baseline characteristics were typical of healthy volunteers Phase 1 Data cutoff: April 14, 2026 BMI – Body Mass Index JADE101 and Placebo 175 mg 350 mg 700 mg 1400 mg All cohorts N 8 8 8 8 32 Age, (yr), Mean (SD) 38.0 (7.86) 44.5 (9.87) 28.0 (9.04) 37.6 (13.70) 37.0 (11.51) Female N (%) 2 (25) 6 (75
Slide 12: JADE101 demonstrated favorable safety profile and was well tolerated across all evaluated doses
JADE101 demonstrated favorable safety profile and was well tolerated across all evaluated doses No severe AEs or deaths All TEAEs were mild/moderate in severity No clinically significant changes in ECGs or vitals No trends of signals in safety labs No cases of IgG ≤3 g/L Well-tolerated locally by SC
Slide 13: Single dose IgA reductions exceeded those reported with first-generation molecules
JADE101 single dose IgA reductions exceeded those reported with first-generation molecules Data cutoff: April 14, 2026 Source: Internal data; IgA responses estimated via noncompartmental analysis of individual JADE101 profiles and internal analyses of mean reported profiles of povetacicept (Davies,
Slide 14: Ultra-high APRIL binding affinity predicted enhanced in vivo potency to lower serum IgA
Ultra-high APRIL binding affinity predicted JADE101’s enhanced in vivo potency to lower serum IgA in humans JADE101 has shown rapid, deep and sustained IgA depletion JADE101 demonstrated compelling in vivo potency to lower IgA PHASE 1 APRIL KD(pM) IgA EC50 (ηM) Jade101 Pove Sibe Ziga Ataci IgA EC50
Slide 15: JADE101 PD modeling supports Q12W maintenance dosing
0 -10 -30 -50 -70 0 8 16 24 32 40 48 JADE101 350 mg SC Q12W maintenance Pove 80 mg SC Q4W Sibe 400 mg SC Q4W JADE101 PD modeling supports Q12W maintenance dosing Deeper IgA reductions simulated over first-generation anti-APRILs JADE101 induction dose (700 mg) predicted to rapidly maximize IgA deplet
Slide 16: IgA reductions for 12 weeks enabled by dose-dependent PK and fAPRIL suppression
Pharmacokinetics fAPRIL JADE101 CONC. (μg/mL) IgA reductions for 12 weeks enabled by dose-dependent PK and rapid, complete, and sustained fAPRIL suppression Date cutoff: April 14, 2026; Source: Internal data. Half-life dependent on dose and dose interval; JADE101 half-life measured at 700 mg inducti
Slide 17: Changes in IgG, IgM and IgE were consistent with selective anti-APRIL MoA
Changes in IgG, IgM and IgE were consistent with the selective anti-APRIL MoA IgG IgM Magnitude of IgG-lowering consistent with relatively IgG-sparing selective- anti-APRIL MoA No cases of IgG ≤ 3 g/L Substantial IgM and IgE reductions PHASE 1 IgE IgG CFB (%) Time (week) IgM CFB (%) Time (week) IgE
Slide 18: Next Steps
JADE101 Next Steps
Slide 19: Plan to evaluate two dosing regimens (Q12W and Q8W) in Phase 2 and Phase 3
Plan to evaluate two dosing regimens (Q12W and Q8W) in Phase 2 and Phase 3 Two dose Phase 3 may enable an accelerated Phase 3 initiation without awaiting Phase 2 data Supports global regulatory expectations for dose-finding Initial induction dose intended to drive ~70% IgA reductions at earlier time
Slide 20: Phase 2 IgAN patient trial initiated; interim data anticipated in 2027
JADE101 Phase 2 IgAN patient trial initiated; interim data anticipated in 2027 Design Randomized, open-label Subcutaneous administration Population Adults with IgAN within 5 yrs Proteinuria ≥0.75g/g eGFR ≥30mL/min/m2 Stable SOC ≥12 weeks Objectives Safety and tolerability UPCR-24 over time (<0.5 g/d
Slide 21: Advancing potentially best-in-class therapies for autoimmune diseases
Program MOA preclinical Phase 1 Phase 2 Phase 3 Potential Indications JADE101 anti-APRIL IgAN JADE201 anti-BAFF-R Multiple systemic AI diseases JADE301 Undisclosed Undisclosed Advancing potentially best-in-class therapies for autoimmune diseases Well-capitalized with $311 million in cash(1); runway
Slide 22: Thank you
Thank you JadeBiosciences.com info@jadebiosciences.com Nasdaq: jbio